Zhaozhi Jiang
Endocrinology, Diabetes & Metabolism · Cumming, GANPI 1558850065
Payments from drug & device makers
Across 84 payments — averaging $25.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$256
- Amgen$221
- Sanofi-aventis U.S. LLC$215
- Tandem Diabetes Care, Inc.$203
- Xeris Pharmaceuticals, Inc.$107
- Corcept Therapeutics$101
- plus $1K from 25 others
What the payments were for
- Food & beverage$2,125100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 12 | $256 |
| Amgen | 10 | $221 |
| Sanofi-aventis U.S. LLC | 5 | $215 |
| Tandem Diabetes Care, Inc. | 4 | $203 |
| Xeris Pharmaceuticals, Inc. | 5 | $107 |
| Corcept Therapeutics | 4 | $101 |
| Radius Health, Inc. | 3 | $98 |
| Chiesi USA, Inc. | 1 | $83 |
| Bayer | 3 | $63 |
| Averitas Pharma Inc. | 2 | $62 |
| Vivus LLC | 3 | $58 |
| Mannkind Corporation | 3 | $57 |
| Medtronic | 3 | $51 |
| Dexcom, Inc. | 2 | $46 |
| Verity Pharmaceuticals Inc. | 2 | $44 |
| Insulet Corporation | 2 | $43 |
| Abbott | 2 | $43 |
| Ascendis Pharma Endocrinology Inc | 2 | $43 |
| Novartis | 2 | $42 |
| Ionis Pharmaceuticals, Inc. | 2 | $41 |
| Kyowa Kirin, Inc. | 2 | $40 |
| BETA Bionics, Inc. | 1 | $29 |
| Neurocrine Biosciences, Inc. | 1 | $29 |
| Astellas Pharma US Inc | 1 | $25 |
| Novo Nordisk | 1 | $24 |
| Sequel Med Tech, LLC | 1 | $22 |
| Boehringer Ingelheim | 1 | $20 |
| Acella Pharmaceuticals, LLC | 1 | $17 |
| Antares Pharma, Inc. | 1 | $15 |
| GSK | 1 | $14 |
| AbbVie | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,125 in reported general payments places this provider in the 40th percentile of 222 endocrinology, diabetes & metabolism providers in Georgia.
See all endocrinology, diabetes & metabolism providers in Georgia →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 29 | $35,515 |
| MounjaroTirzepatide | 24 | $29,473 |
| TrulicityDulaglutide | 12 | $11,404 |
| Humalog Kwikpen U-100Insulin Lispro | 17 | $4,544 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 36 | $3,776 |
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 41 | $3,112 |
| Glipizide | 34 | $451 |
| Levothyroxine Sodium | 54 | $382 |
| Metformin Hcl ErMetformin Hcl | 24 | $191 |
| Methimazole | 26 | $143 |
| Metformin Hcl | 11 | $38 |
| Dexamethasone | 14 | $16 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $256 | $40,87736 claims |
| Novo NordiskOzempic | $24 | $35,51529 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 222 endocrinology, diabetes & metabolism providers in Georgia.
Other endocrinology, diabetes & metabolism in Cumming
- Bruce BodeAtlanta$18.3M
- Gulliermo UmpierrezAtlanta$6.6M
- John ReedRoswell$5.7M
- Thomas JonesMacon$4.8M
- Steven LeichterColumbus$3.1M
- Jason BernerJasper$2.6M
- Ashwini GoreMacon$2.6M
- Adeniyi OdugbesanLawrenceville$1.8M
- David RobertsonAtlanta$1.7M
- Thomas ZieglerAtlanta$1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.